Vascular Technologies Inc., and the Ultroid Organization Announces the Opening of a Clinic in London's Famous Harley Street Medical District

    TAMPA, FL, November 07, 2014 /24-7PressRelease/ -- Vascular Technologies Inc. and its wholly owned Ultroid subsidiaries (the "Company"), today announced that the first United Kingdom clinic, located in Canterbury, UK, has reached its initial goals, and a second clinic has been opened in London's famous Harley Street medical district. The Harley Street center is presently staffed by two medical doctors who provide the proprietary Ultroid treatments. A third clinic is scheduled to open in Taunton (in southwest UK) within 2 weeks, with additional UK locations scheduled to open within the next months, including a second Harley Street location. Each will be open one or more days per week, which is typical for the United Kingdom, and can quickly expand the number of operating days in keeping with increased demand. This improves the geographic accessibility of physicians providing Ultroid treatments.

Michael Cao, the Company's Founder and Executive Chairman, explained that "Ultroid is already demonstrating its value in the United Kingdom, and patients are learning of the Ultroid procedures and its outstanding results through UK publicity, advertising, digital media, and word of mouth."

The Company derives revenue from the sale of the Ultroid devices as well as the required single-use, disposable probes and anoscopes, all of which are manufactured in the United States.

Mr. Cao went on to comment that "the accomplishments of Dr. Mark Hudson-Peacock, Medical Director of Ultroid UK and his associates, have clearly proven the value of Ultroid treatments to suffering patients in the UK, and have demonstrated the viability of the business model the Company plans to expand to other nations."

ABOUT VASCULAR TECHNOLOGIES INC. AND ULTROID
Vascular Technologies Inc., a Nevada corporation and its several wholly owned Florida Ultroid subsidiaries, have developed, patented, and obtained FDA and international clearance for the Ultroid system and procedure, providing a permanent solution for symptomatic hemorrhoids, utilizing a disposable, single use element combined with a painless milliamp and minimal voltage direct current. The procedure, which has been utilized more than 120,000 times for the treatment and resolution of symptomatic hemorrhoids, is safe, non-surgical, requires no anesthetic, minimizes the pain of the hemorrhoid and its treatment, requires no recuperation time, can be utilized for all four grades of internal and mixed hemorrhoids, and is reimbursable by all major insurance organization as well as Medicare and Worker Compensation programs. The Ultroid procedure is the exclusive treatment of various hemorrhoid clinics within the United States, the UK (including a Harley Street clinic in London), and additional clinics are planned for the Americas, Europe, the Middle East, and Asia. The Ultroid procedure can be utilized by family practice physicians and internists, OB/GYNs, gastroenterologists, clinics, surgical centers, hospitals, and others.

Forward Looking Statements:
Statements in this press release that are not purely historical facts, including statements regarding the Company's beliefs, expectations, intentions or strategies for the future, may be "forward-looking statements" under the Private Securities Litigation Reform Act of 1996. Such statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as "plan," "may," "expect," "anticipate," "intend," "estimate," or "continue," or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward-looking statements are speculative, and there are certain risks and uncertainties that could cause actual events or results to differ from those referred to in such forward-looking statements. This disclosure highlights some of the important risks regarding our business. Specifically, the reader should not place undue reliance on statements regarding our ability to develop future activities, or to make successful strategic decisions and investments.

Ultroid maintains an informational website at: www.ultroid.com, and its UK strategic partner's website is at: www.ultroiduk.com.

The Company's Investment Banking Consultant is Dawson James Securities, Member: FINRA/SIPC, 1 South Federal Highway, Boca Raton, Fl 33432, attention: Mr. Carlo Corzine, +1.561.391.5555.

For further information and investor relations contact:

Mark Kallan, President
Vascular Technologies Inc.
3140 W. Kennedy Boulevard
Tampa, Fl 33609
Telephone: +1.727.898.0717
Email: [email protected]

# # #